On this page
MPL
MPL proto-oncogene, thrombopoietin receptor
The MPL gene provides instructions for producing the thrombopoietin receptor, a protein critical for the development and proliferation of blood cells, particularly megakaryocytes which produce platelets. MPL encodes the thrombopoietin receptor, a cell surface protein that plays a vital role in haematopoiesis, the process of blood cell formation.
MPL is located on the short (p) arm of chromosome 1, at band 1p34.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 1 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The MPL gene, also known as myeloproliferative leukaemia protein, contains the genetic instructions for the thrombopoietin receptor. This receptor is a crucial component in regulating blood cell production, especially for megakaryocytes and platelets. Abnormalities in MPL can result in various haematological conditions, impacting the body's capacity for blood clotting or leading to other bone marrow disorders.
What the gene does
The protein produced by the MPL gene, the thrombopoietin receptor, is a cell surface receptor that binds to thrombopoietin (TPO). TPO is a hormone that stimulates platelet formation. When TPO attaches to the MPL receptor, an intracellular signalling pathway called the JAK/STAT pathway is activated. This process sends chemical signals into the cell's nucleus, which promotes the growth, division, and differentiation of various blood cell precursors, especially megakaryocytes. These megakaryocytes then mature to create platelets, which are crucial for normal blood clotting. The thrombopoietin receptor is also believed to contribute to the maintenance of haematopoietic stem cells, which are progenitor cells that can develop into all types of blood cells.
Video: Genetics 101
Chromosome location
The MPL gene is situated on the short (p) arm of chromosome 1 at position 34.2, specifically 1p34.2. This genomic location dictates where the gene resides within the human genome and contributes to its expression patterns.
Protein structure
The MPL protein is composed of 635 amino acids and features several distinct structural elements. It includes two Fibronectin type-III domains: Fibronectin type-III 1, located between amino acids 172-281, and Fibronectin type-III 2, spanning amino acids 392-486. A Disordered region is found within amino acids 205-232. Additionally, the protein contains key functional motifs, including the WSXWS motif (amino acids 474-478) and the Box 1 motif (amino acids 528-536), which are important for receptor activation and signalling.
Key variants
Variants within the MPL gene can alter the structure or function of the thrombopoietin receptor, leading to a range of clinical presentations. These genetic changes can affect how the receptor binds to thrombopoietin or how it transmits signals inside the cell, influencing blood cell production. Different types of variants may result in either reduced or enhanced receptor activity, correlating with distinct haematological conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1033C>T | p.Gln345Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.1145del | p.Pro382fs | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.11G>A | p.Trp4Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.139del | p.Asp47fs | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia 1 |
c.1469-2A>T | - | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.1545G>A | p.Trp515Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia 1 |
c.1671dup | p.Asp558fs | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.209del | p.Pro70fs | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia 1 |
c.292C>T | p.Gln98Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
c.407C>T | p.Pro136Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital amegakaryocytic thrombocytopenia |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the MPL gene are associated with inherited conditions affecting blood cell production. One such condition is Congenital amegakaryocytic thrombocytopenia, a rare autosomal recessive disorder characterised by very low numbers of megakaryocytes and platelets, which can lead to bone marrow failure. Other conditions like essential thrombocythaemia and primary myelofibrosis, primarily linked to acquired variants, can also involve MPL.
Inheritance pattern
Conditions caused by pathogenic MPL variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The MPL gene is included in several NHS Genomic Medicine Service national test panels. These panels are used for diagnosing and managing conditions related to blood disorders. Specifically, MPL is part of the 'Bleeding and platelet disorders', 'Cytopenia - NOT Fanconi anaemia', 'Cytopenias and congenital anaemias', 'Inherited bleeding disorders', and 'Thrombocythaemia' green R-panels.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the primary function of the MPL gene?
The MPL gene provides instructions for the thrombopoietin receptor, which is crucial for the proliferation of megakaryocytes, the cells that produce platelets necessary for blood clotting.
What is Congenital amegakaryocytic thrombocytopenia?
Congenital amegakaryocytic thrombocytopenia is a rare inherited condition caused by MPL variants, characterised by a severe deficiency of megakaryocytes and platelets from birth, which can lead to bone marrow failure.
How does the thrombopoietin receptor work?
The thrombopoietin receptor activates the JAK/STAT signalling pathway upon binding with thrombopoietin, which then stimulates the growth and differentiation of blood cells, especially those involved in platelet formation.
References
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010. PMID: 20428194
- Ding J, Komatsu H, Iida S. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009. PMID: 19483125
- Chaligné R, Tonetti C, Besancenot R. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008. PMID: 18528423
- Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Human mutation. 2006. PMID: 16470591
- Pikman Y, Lee BH, Mercher T. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine. 2006. PMID: 16834459